Patients with low platelets and hemoglobin in myelofibrosis can be treated with medications such as testosterone propionate, danazol, or transfusion of red blood cells and platelets. 1. Patients with myelofibrosis mainly show symptoms such as anemia, bleeding and extramedullary hematopoiesis, and the patients’ platelets and hemoglobin will decrease. Patients with anemia can take drugs such as testosterone propionate, danazol, hydroxymetholone to promote the differentiation and maturation of young erythrocytes and improve the hematopoietic function of bone marrow. Patients with severe anemia can be transfused with red blood cells. 2. Patients with low platelet count can be transfused with platelets, and drugs such as Eltrombopag can also be given to promote platelet generation. Myelofibrosis is a kind of myeloproliferative disease, and the age of onset of patients is 50~70 years old, and it is also common in infants. The cause of the disease is not yet clear, may be related to the stimulation of hematopoietic stem cells, may also be related to chemical stimulation, infection, tumor and other factors. Patients are advised to seek timely medical treatment and standardize the treatment under the guidance of doctors.